Patients with high fracture risk should receive one out of the following three drugs: alendronate, risedronate or zoledronate, if they use steroids in a dose of <5 mg/day, even for <1 month, and ...

Postmenopausal women with hormone receptor–positive EBC were assigned to one of three strata by risk of fragility fracture. Patients with the highest risk (H) received anastrozole 1 mg/d plus ...

On May 20, the Food and Drug Administration approved risedronate (brand name Actonel) for the prevention and treatment of postmenopausal osteoporosis. A once-a-week, 35 mg dose of risedronate is ...

Adults prescribed risedronate who discontinued use for 1 year had a higher risk for mortality than adults who continued treatment (HR = 1.66; 95% CI, 1.01-2.73).